186 related articles for article (PubMed ID: 30909817)
1. Molecular dynamics study of HDAC8-largazole analogues co-crystals for designing potential anticancer compounds.
Dewaker V; Srivastava PN; Verma S; Prabhakar YS
J Biomol Struct Dyn; 2020 Mar; 38(4):1197-1213. PubMed ID: 30909817
[TBL] [Abstract][Full Text] [Related]
2. Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8.
Decroos C; Clausen DJ; Haines BE; Wiest O; Williams RM; Christianson DW
Biochemistry; 2015 Mar; 54(12):2126-35. PubMed ID: 25793284
[TBL] [Abstract][Full Text] [Related]
3. Investigation of HDAC8-ligands' intermolecular forces through molecular dynamics simulations: profiling of non-bonding energies to design potential compounds as new anti-cancer agents.
Dewaker V; Srivastava AK; Arora A; Prabhakar YS
J Biomol Struct Dyn; 2021 Aug; 39(13):4726-4751. PubMed ID: 32578494
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases.
Cole KE; Dowling DP; Boone MA; Phillips AJ; Christianson DW
J Am Chem Soc; 2011 Aug; 133(32):12474-7. PubMed ID: 21790156
[TBL] [Abstract][Full Text] [Related]
5. Examining the stability of binding modes of the co-crystallized inhibitors of human HDAC8 by molecular dynamics simulation.
Uba AI; Weako J; Keskin Ö; Gürsoy A; Yelekçi K
J Biomol Struct Dyn; 2020 Apr; 38(6):1751-1760. PubMed ID: 31057077
[TBL] [Abstract][Full Text] [Related]
6. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Zhou H; Wang C; Deng T; Tao R; Li W
J Biomol Struct Dyn; 2018 Jun; 36(8):1966-1978. PubMed ID: 28632421
[TBL] [Abstract][Full Text] [Related]
7. Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation.
Dewaker V; Srivastava PN; Verma S; Srivastava AK; Prabhakar YS
J Biomol Struct Dyn; 2022; 40(24):13432-13455. PubMed ID: 34662251
[TBL] [Abstract][Full Text] [Related]
8. Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies.
Sixto-López Y; Gómez-Vidal JA; Correa-Basurto J
Appl Biochem Biotechnol; 2014 Aug; 173(7):1907-26. PubMed ID: 24888409
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of c7-demethyl largazole analogues.
Chen F; Gao AH; Li J; Nan FJ
ChemMedChem; 2009 Aug; 4(8):1269-72. PubMed ID: 19431162
[No Abstract] [Full Text] [Related]
10. Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships.
Poli G; Di Fabio R; Ferrante L; Summa V; Botta M
ChemMedChem; 2017 Dec; 12(23):1917-1926. PubMed ID: 29117473
[TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
Reddy DN; Ballante F; Chuang T; Pirolli A; Marrocco B; Marshall GR
J Med Chem; 2016 Feb; 59(4):1613-33. PubMed ID: 26681404
[TBL] [Abstract][Full Text] [Related]
12. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
Kashyap K; Kakkar R
J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
[TBL] [Abstract][Full Text] [Related]
13. Largazole Analogues Embodying Radical Changes in the Depsipeptide Ring: Development of a More Selective and Highly Potent Analogue.
Almaliti J; Al-Hamashi AA; Negmeldin AT; Hanigan CL; Perera L; Pflum MK; Casero RA; Tillekeratne LM
J Med Chem; 2016 Dec; 59(23):10642-10660. PubMed ID: 27809521
[TBL] [Abstract][Full Text] [Related]
14. Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation.
Bhansali P; Hanigan CL; Casero RA; Tillekeratne LM
J Med Chem; 2011 Nov; 54(21):7453-63. PubMed ID: 21936551
[TBL] [Abstract][Full Text] [Related]
15. A comparative study based on docking and molecular dynamics simulations over HDAC-tubulin dual inhibitors.
Hassanzadeh M; Bagherzadeh K; Amanlou M
J Mol Graph Model; 2016 Nov; 70():170-180. PubMed ID: 27750186
[TBL] [Abstract][Full Text] [Related]
16. Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole.
Clausen DJ; Smith WB; Haines BE; Wiest O; Bradner JE; Williams RM
Bioorg Med Chem; 2015 Aug; 23(15):5061-5074. PubMed ID: 26054247
[TBL] [Abstract][Full Text] [Related]
17. Potent non-hydroxamate inhibitors of histone deacetylase-8: Role and scope of an isoindolin-2-yl linker with an α-amino amide as the zinc-binding unit.
Greenwood SOR; Chan AWE; Hansen DF; Marson CM
Bioorg Med Chem Lett; 2020 Mar; 30(5):126926. PubMed ID: 31952961
[TBL] [Abstract][Full Text] [Related]
18. Developing Hispolon-based novel anticancer therapeutics against human (NF-κβ) using
Paul M; Kumar Panda M; Thatoi H
J Biomol Struct Dyn; 2019 Sep; 37(15):3947-3967. PubMed ID: 30295165
[TBL] [Abstract][Full Text] [Related]
19. Thiol versus hydroxamate as zinc binding group in HDAC inhibition: An ab initio QM/MM molecular dynamics study.
Gong W; Wu R; Zhang Y
J Comput Chem; 2015 Nov; 36(30):2228-35. PubMed ID: 26452222
[TBL] [Abstract][Full Text] [Related]
20. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]